ISCO OTC
International Stem Cell Corporation
1W: -17.1%
1M: -26.4%
3M: +62.0%
YTD: +107.1%
1Y: +123.1%
3Y: +123.1%
5Y: -50.0%
$0.29
-0.01 (-3.01%)
Weekly Expected Move ±19.5%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$9M
+0.2% ▲
5Y CAGR: +5.0%
Gross Profit
$5M
-4.8% ▼
5Y CAGR: +3.1%
Operating Income
-$267K
-292.6% ▼
Net Income
-$418K
-100.0% ▼
EPS (Diluted)
$-0.05
-91.6% ▼
EBITDA
-$267K
-288.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $7M | $8M | $8M | $9M | $9M |
| YoY Growth | +0.7% | +14.0% | -4.8% | +16.6% | +0.2% |
| Cost of Revenue | $3M | $3M | $3M | $4M | $4M |
| Gross Profit | $4M | $5M | $5M | $5M | $5M |
| Gross Margin | 59.1% | 60.0% | 59.2% | 58.6% | 55.7% |
| R&D Expenses | $695K | $492K | $511K | $657K | $684K |
| SG&A Expenses | $5M | $5M | $5M | $5M | $5M |
| Operating Expenses | $6M | $5M | $5M | $5M | $5M |
| Operating Income | -$2M | -$196K | -$663K | -$68K | -$267K |
| Operating Margin | -26.8% | -2.4% | -8.5% | -0.7% | -2.9% |
| Interest Expense | $128K | $135K | $139K | $145K | -$6K |
| Income Before Tax | -$899K | -$331K | -$131K | -$209K | -$418K |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$1M | -$466K | -$131K | -$209K | -$418K |
| Net Margin | -14.5% | -5.7% | -1.7% | -2.3% | -4.6% |
| EPS (Diluted) | $-0.13 | $-0.06 | $-0.02 | $-0.03 | $-0.05 |
| EBITDA | -$220K | $22K | $202K | $142K | -$267K |
| Shares Outstanding | 8M | 8M | 8M | 8M | 8M |